Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dana-Farber Cancer Institute issued the following statement today:
We are very pleased that the U.S. Court of Appeals for the Federal Circuit upheld the ruling of the U.S. District Court for the District of Massachusetts that Dana-Farber Cancer Institute scientist Gordon Freeman and a collaborator are joint inventors on six critical immunotherapy patents.
After a lengthy trial in May 2019, Judge Patti B. Saris found “clear and convincing evidence” that Dr. Freeman made significant contributions to conceiving a novel method of treating cancer by harnessing the PD-1/PD-L1 pathway. In a unanimous decision, the Court of Appeals agreed.
Dana-Farber is continuing plans to license the technology, which is embodied in several of the newest immunotherapy drugs, to additional companies seeking to develop anti-PD-1 and anti-PDL-1 cancer therapies.
Press release from initial ruling in May 2019: www.dana-farber.org/newsroom/news-releases/2019/u-s--district-court-rules-dana-farber-scientist-is-an-inventor--on-six-critical-immunotherapy-patents/
Posted on July 14, 2020
Media Contacts
For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to media@dfci.harvard.edu.
Gordon Freeman, PhD